caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1568411049

William MatsuiM.D.

PRACTICEJOHNS HOPKINS HOSPITALSee all providers at this practice →
Hematology-OncologyBaltimore, MDI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where William Matsui's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 7 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Douglas Gladstone
Medical Oncology · Baltimore, MD
1352
Johns Hopkins University
Clinical Laboratory · Baltimore, MD
1317
Carol Huff
Medical Oncology · Baltimore, MD
13283
Milena Vuica-Ross
Pathology · Baltimore, MD
1331
David Feigin
Diagnostic Radiology · Baltimore, MD
1336
Kathleen Burns
Pathology · Baltimore, MD
1217
Patrizio Caturegli
Pathology · Baltimore, MD
1145
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
31
Unique beneficiaries
—
Total services
61
Distinct HCPCS
1
Medicare payment
$6K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 175 Hematology-Oncology providers in MD — bottom quintile (cohort median 11,156).
PRESCRIBING · PART D · 2024
Total Rx claims
135
Beneficiaries
—
Total drug cost
$2.4M
Distinct drugs
2
Brand share
74.8%
Top prescribed drugs
Lenalidomide58 claims
Pomalidomide43 claims
Lenalidomide34 claims
QUALITY · MIPS · 2024
Final MIPS score
79.3
Quality
76.3
Cost
74.6
Improvement activities
40.0
Promoting interop.
0.0
Payment adjustment
0.18%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.